Clinical Trial Update: Safety and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Healthy Subjects Aged 18 Years and Above [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating the safety and immunogenicity of a recombinant RSV vaccine produced in CHO cells in healthy adults aged 18 years and older.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Recombinant RSV Vaccine (CHO Cell) (recombinant RSV vaccine produced in CHO cells)

Snippet

Sponsor: MAXVAX Biotechnology Limited Liability Company | Conditions: Respiratory Syncytial Virus (RSV) | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING